1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Analysis & Statistics in Asia Countries, July 2019

Mental Health Analysis & Statistics in Asia Countries, July 2019

1-30 of about 100 reports

Alzheimer’s Disease Market and Forecast Analysis 2034

Alzheimer’s Disease Market and Forecast Analysis 2034

  • $ 22000
  • Industry report
  • February 2019

Disease OverviewAlzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer’s disease is the most common ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • December 2018

SummaryKyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines.The company offers ethical drugs including ...

  • Industries : Pharmaceutical
  • Countries : United States, Japan
Mapi Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mapi Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2018

SummaryMapi Pharma Ltd (Mapi Pharma) is a clinical stage pharmaceutical company that offers development of active pharmaceutical ingredients and formulations, and life cycle management products.The company’s ...

  • Industries : Pharmaceutical
  • Countries : China, Israel
Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Therapix Biosciences Ltd (TRPX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2018

SummaryTherapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central ...

  • Industries : Pharmaceutical, Therapy
  • Countries : Israel
Israel Institute of Technology - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Israel Institute of Technology - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2018

SummaryIsrael Institute of Technology (Technion) is a research university that offers science and technology programs.The university offers various undergraduate and graduate programs in biology, biomedical ...

  • Industries : Pharmaceutical
  • Countries : Israel
South Korea Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

South Korea Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • Industry report
  • November 2018

South Korea Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and OthersSummaryGlobalData’s new report, South Korea Neurology ...

  • Industries : Health Services, Healthcare, Patient Monitoring, Medical Device, Mental Health, Pathology
  • Countries : South Korea, East Asia
China Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

China Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • Industry report
  • November 2018

China Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and OthersSummaryGlobalData’s new report, China Neurology Devices ...

  • Industries : Health Services, Healthcare, Patient Monitoring, Medical Device, Mental Health, Pathology
  • Countries : China, East Asia
Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • Industry report
  • November 2018

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and OthersSummaryGlobalData’s new report, Japan Neurology Devices ...

  • Industries : Health Services, Healthcare, Patient Monitoring, Medical Device, Mental Health, Pathology
  • Countries : Japan, East Asia
India Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

India Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • Industry report
  • November 2018

India Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and OthersSummaryGlobalData’s new report, India Neurology Devices ...

  • Industries : Health Services, Healthcare, Patient Monitoring, Mental Health, Medical Device, Pathology
  • Countries : India, South Asia
ViroMed Co Ltd (084990) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ViroMed Co Ltd (084990) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummaryViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases.The company provides ...

  • Industries : Pharmaceutical, Pathology, Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Healthcare
  • Countries : South Korea, World, United States
Pharnext SA (ALPHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharnext SA (ALPHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummaryPharnext SA (Pharnext), formerly Pharnext SAS is a biopharmaceutical company that develops novel therapies for severe neurodegenerative diseases.The company offers pleotherapy, a proprietary research ...

  • Industries : Pharmaceutical, Medical Biotechnology, Mental Health
  • Countries : France, China, United States, World
Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • Company report
  • October 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018SummaryAccording ...

  • Industries : Pathology, Pharmaceutical, Therapy, Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, Brazil, World, United States, Canada
NeuroDerm Ltd - Medical Equipment - Deals and Alliances Profile

NeuroDerm Ltd - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummaryNeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinson’s disease and central nervous system ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Israel
Brainsway Ltd (BRIN) - Medical Equipment - Deals and Alliances Profile

Brainsway Ltd (BRIN) - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2018

SummaryBrainsway Ltd (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychopathological ...

  • Industries : Medical Device, Medical Supply, Mental Health
  • Countries : United States, Israel
Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

  • $ 3995
  • Industry report
  • July 2018

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027SummaryAmyotrophic Lateral Sclerosis (ALS) is often referred to as "Lou Gehrig’s Disease" after the famous baseball player who was diagnosed ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, World, Germany, United Kingdom
Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

  • $ 10995
  • Industry report
  • July 2018

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027SummaryAmyotrophic Lateral Sclerosis (ALS) drug sales in 2017 were approximately $187M across the seven major markets - the US, 5EU ...

  • Industries : Therapy, Mental Health, Pharmaceutical, Pathology
  • Countries : United States, World, Japan
Epilepsy Forecast and Market Analysis to 2035

Epilepsy Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWEpilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Restless Legs Syndrome - Pipeline Review, H2 2018

Restless Legs Syndrome - Pipeline Review, H2 2018

  • $ 2000
  • Company report
  • July 2018

Restless Legs Syndrome - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2018, provides ...

  • Industries : Mental Health, Pathology, Pharmaceutical
  • Countries : United States, World, Japan
Parkinson’s disease forecast and market analysis to 2035

Parkinson’s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

Disease OverviewParkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
The 2019-2024 Outlook for Epilepsy Drugs in India

The 2019-2024 Outlook for Epilepsy Drugs in India

  • $ 595
  • Industry report
  • June 2018

This study covers the latent demand outlook for epilepsy drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) ...

  • Industries : Mental Health
  • Countries : India
The 2019-2024 Outlook for Epilepsy Drugs in China

The 2019-2024 Outlook for Epilepsy Drugs in China

  • $ 595
  • Industry report
  • June 2018

This study covers the latent demand outlook for epilepsy drugs across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities ...

  • Industries : Mental Health
  • Countries : China
Duopa

Duopa

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Azilect

Azilect

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAzilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, Europe, Japan, European Union
Neupro

Neupro

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewNeupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Nouriast

Nouriast

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewNouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States
Ongentys

Ongentys

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewOngentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union, North America
The 2019-2024 Outlook for Mental Disorder Drugs in India

The 2019-2024 Outlook for Mental Disorder Drugs in India

  • $ 595
  • Industry report
  • June 2018

This study covers the latent demand outlook for mental disorder drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings ...

  • Industries : Mental Health
  • Countries : India
The 2019-2024 Outlook for Epilepsy Treatments in India

The 2019-2024 Outlook for Epilepsy Treatments in India

  • $ 595
  • Industry report
  • June 2018

This study covers the latent demand outlook for epilepsy treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings ...

  • Industries : Mental Health
  • Countries : India
The 2019-2024 Outlook for Epilepsy Treatments in China

The 2019-2024 Outlook for Epilepsy Treatments in China

  • $ 595
  • Industry report
  • June 2018

This study covers the latent demand outlook for epilepsy treatments across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities ...

  • Industries : Mental Health
  • Countries : China

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on